华仁药业
(300110)
| 流通市值：37.21亿 | | | 总市值：37.24亿 |
| 流通股本：11.81亿 | | | 总股本：11.82亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 185,489,224.63 | 138,973,139.03 | 222,890,633.82 | 211,064,591.05 |
| 应收票据及应收账款 | 508,451,507.77 | 493,016,522.08 | 513,740,682.17 | 519,505,843.27 |
| 其中：应收票据 | 8,974,741.36 | 8,881,287.2 | 6,645,456.63 | 6,688,247.26 |
| 应收账款 | 499,476,766.41 | 484,135,234.88 | 507,095,225.54 | 512,817,596.01 |
| 应收款项融资 | 77,271,979.17 | 62,190,448.64 | 85,238,461.85 | 77,120,233.91 |
| 预付款项 | 43,675,751.63 | 18,991,170.31 | 33,075,466.47 | 27,476,929.01 |
| 其他应收款合计 | 28,776,649.04 | 20,992,442.82 | 37,067,111.84 | 35,088,306.8 |
| 存货 | 245,724,313 | 241,508,622.4 | 252,561,995.35 | 279,057,706.19 |
| 其他流动资产 | 16,681,558.29 | 18,203,471.8 | 17,807,964.58 | 19,766,034.3 |
| 流动资产合计 | 1,106,070,983.53 | 993,875,817.08 | 1,162,382,316.08 | 1,169,079,644.53 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 15,984,624 | 15,984,624 | 15,984,624 | 15,984,624 |
| 其他非流动金融资产 | - | - | 0 | - |
| 投资性房地产 | 8,739,649.32 | 8,811,709.86 | 8,883,770.4 | 8,955,830.94 |
| 固定资产 | 972,409,744.62 | 992,152,153.89 | 967,329,501.69 | 978,939,852.08 |
| 在建工程 | 96,242,972.15 | 100,025,374.03 | 111,395,219.1 | 103,695,060.28 |
| 生产性生物资产 | - | - | 0 | - |
| 油气资产 | - | - | 0 | - |
| 使用权资产 | 1,337,884.49 | 1,416,590.75 | 1,233,084.74 | 69,684.53 |
| 无形资产 | 278,509,200.88 | 284,049,114.33 | 288,914,895.02 | 290,915,232.25 |
| 开发支出 | 3,450,575.99 | 3,252,524.39 | 2,811,112.22 | 6,194,146.11 |
| 商誉 | 207,894,530.07 | 207,894,530.07 | 732,611,620.38 | 732,611,620.38 |
| 长期待摊费用 | 5,467,733.39 | 6,470,374.49 | 8,997,956.78 | 9,923,784.06 |
| 递延所得税资产 | 70,904,061.46 | 70,989,989.99 | 59,484,397.43 | 59,341,627.36 |
| 其他非流动资产 | 20,653,742.52 | 17,079,321.29 | 36,780,209.77 | 49,252,690.9 |
| 非流动资产合计 | 1,681,594,718.89 | 1,708,126,307.09 | 2,234,426,391.53 | 2,255,884,152.89 |
| 资产总计 | 2,787,665,702.42 | 2,702,002,124.17 | 3,396,808,707.61 | 3,424,963,797.42 |
| 流动负债: | | | | |
| 短期借款 | 437,197,928.51 | 330,423,835.62 | 485,932,876.71 | 503,017,390.41 |
| 应付票据及应付账款 | 179,741,472.05 | 199,904,877.91 | 115,500,434.06 | 120,224,704.15 |
| 应付账款 | 179,741,472.05 | 199,904,877.91 | 115,500,434.06 | 120,224,704.15 |
| 预收款项 | 1,693,181.02 | 1,693,181.02 | 0 | - |
| 合同负债 | 29,503,932.81 | 33,706,137.41 | 33,122,072.58 | 32,683,097.6 |
| 应付职工薪酬 | 15,075,540.87 | 15,507,032.69 | 17,346,403.11 | 16,560,315.64 |
| 应交税费 | 30,626,148.83 | 21,205,743.8 | 15,871,518.84 | 12,007,082.8 |
| 其他应付款合计 | 261,505,886.32 | 235,229,941.9 | 299,101,401.93 | 283,262,598.97 |
| 一年内到期的非流动负债 | 389,289,101.19 | 633,864,417.75 | 591,492,562.4 | 613,252,562.4 |
| 其他流动负债 | 4,055,624.8 | 2,996,947.35 | 4,305,869.43 | 2,960,828.13 |
| 流动负债合计 | 1,348,688,816.4 | 1,474,532,115.45 | 1,562,673,139.06 | 1,583,968,580.1 |
| 非流动负债: | | | | |
| 长期借款 | 464,134,925 | 270,219,200 | 366,131,145 | 385,945,250 |
| 租赁负债 | 1,097,490.18 | 785,973.29 | 961,926.04 | - |
| 长期应付款 | 0 | 0 | - | - |
| 长期应付职工薪酬 | 0 | 0 | - | - |
| 递延收益 | 8,286,985.29 | 7,049,148.55 | 131,559.37 | 131,559.37 |
| 递延所得税负债 | 39,593,708.29 | 40,355,318.62 | 41,063,477.64 | 41,825,087.98 |
| 非流动负债合计 | 513,113,108.76 | 318,409,640.46 | 408,288,108.05 | 427,901,897.35 |
| 负债合计 | 1,861,801,925.16 | 1,792,941,755.91 | 1,970,961,247.11 | 2,011,870,477.45 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,182,212,982 | 1,182,212,982 | 1,182,212,982 | 1,182,212,982 |
| 资本公积 | 528,044,115.47 | 528,044,115.47 | 528,044,115.47 | 528,044,115.47 |
| 盈余公积 | 90,528,384.95 | 90,528,384.95 | 90,616,259.13 | 90,528,384.95 |
| 未分配利润 | -946,940,609.31 | -962,899,211.04 | -445,507,273.74 | -462,666,310.24 |
| 归属于母公司股东权益合计 | 853,844,873.11 | 837,886,271.38 | 1,355,366,082.86 | 1,338,119,172.18 |
| 少数股东权益 | 72,018,904.15 | 71,174,096.88 | 70,481,377.64 | 74,974,147.79 |
| 股东权益合计 | 925,863,777.26 | 909,060,368.26 | 1,425,847,460.5 | 1,413,093,319.97 |
| 负债和股东权益合计 | 2,787,665,702.42 | 2,702,002,124.17 | 3,396,808,707.61 | 3,424,963,797.42 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-30 | 2025-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |